Oncology biosimilars: New developments and future directions.

Bachu RD, Abou-Dahech M, Balaji S, Boddu SHS, Amos S, Singh V, Babu RJ, Tiwari AK.

Open source

DOI: 10.1002/cnr2.1720
Published: 2022-10-04
Container: Cancer Rep (Hoboken)
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1002/cnr2.1720,
  title = {Oncology biosimilars: New developments and future directions.},
  author = {Bachu RD and  Abou-Dahech M and  Balaji S and  Boddu SHS and  Amos S and  Singh V and  Babu RJ and  Tiwari AK.},
  year = {2022},
  journal = {Cancer Rep (Hoboken)},
  doi = {10.1002/cnr2.1720},
  url = {https://doi.org/10.1002/cnr2.1720}
}

RIS

TY  - JOUR
TI  - Oncology biosimilars: New developments and future directions.
AU  - Bachu RD
AU  -  Abou-Dahech M
AU  -  Balaji S
AU  -  Boddu SHS
AU  -  Amos S
AU  -  Singh V
AU  -  Babu RJ
AU  -  Tiwari AK.
PY  - 2022
JO  - Cancer Rep (Hoboken)
DO  - 10.1002/cnr2.1720
UR  - https://doi.org/10.1002/cnr2.1720
ER  -

APA

RD, B., M, A., S, B., SHS, B., S, A., V, S., RJ, B., & AK., T. (2022). Oncology biosimilars: New developments and future directions.. Cancer Rep (Hoboken). https://doi.org/10.1002/cnr2.1720

Source records

europe-pmc · retrieved 2026-09-25T21:12:05.975Z
doaj · retrieved 2026-09-25T21:12:05.978Z